Additional Supporting Information may be found in the online version of this article.

hep26526-sup-0001-suppFig1.tif2850KSupporting Information Fig. 1
hep26526-sup-0002-suppFig2.tif2658KSupporting Information Fig. 2
hep26526-sup-0003-suppFig3.tif2716KSupporting Information Fig. 3
hep26526-sup-0004-suppFig4.tif2873KSupporting Information Fig. 4
hep26526-sup-0005-suppFig5.tif2986KSupporting Information Fig. 5
hep26526-sup-0006-suppFig6.tif2819KSupporting Information Fig. 6
hep26526-sup-0007-suppFig7.tif2715KSupporting Information Fig. 7
hep26526-sup-0008-suppFig8.tif3611KSupporting Information Fig. 8
hep26526-sup-0009-suppTab1.doc68KSuppl. Table 1. Antibodies for Immunostaining and Western blot
hep26526-sup-00010-suppTab2.doc41KSuppl. Table 2. Sequences of primers and probes used for quantitative RT-PCR
hep26526-sup-00011-suppTab3.doc32KSuppl. Table 3. Relationship between Shc labeling indices (% positive hepatoma cells/hepatocytes) and clinical parameters associated with hepatocarcinogenesis and liver function
hep26526-sup-00012-suppTab4.doc66KSuppl. Table 4. Individual sizes and weights of tumors from heat treated HEPG2 cells in nude mice
hep26526-sup-00013-suppInfo.doc41KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.